These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 9032990)
1. Effect of glycosylation on antibody function: implications for genetic engineering. Wright A; Morrison SL Trends Biotechnol; 1997 Jan; 15(1):26-32. PubMed ID: 9032990 [TBL] [Abstract][Full Text] [Related]
2. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines. Vestrheim AC; Moen A; Egge-Jacobsen W; Bratlie DB; Michaelsen TE Scand J Immunol; 2013 May; 77(5):419-28. PubMed ID: 23488770 [TBL] [Abstract][Full Text] [Related]
3. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853 [TBL] [Abstract][Full Text] [Related]
4. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Jefferis R Trends Pharmacol Sci; 2009 Jul; 30(7):356-62. PubMed ID: 19552968 [TBL] [Abstract][Full Text] [Related]
5. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. Wright A; Morrison SL J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299 [TBL] [Abstract][Full Text] [Related]
6. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965 [TBL] [Abstract][Full Text] [Related]
7. Human antibodies from phage display libraries: expression of recombinant full length immunoglobulin G specific to the hepatitis C virus E2 glycoprotein. Bugli F; Graffeo R; Pescatori M; Paroni Sterbini F; Torelli R; Masucci L; Manzara S; Fadda G New Microbiol; 2009 Oct; 32(4):341-9. PubMed ID: 20128440 [TBL] [Abstract][Full Text] [Related]
8. Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24. Kemminer SE; Conradt HS; Nimtz M; Sagi D; Peter-Katalinić J; Diekmann O; Drmić I; Müthing J Biotechnol Prog; 2001; 17(5):809-21. PubMed ID: 11587568 [TBL] [Abstract][Full Text] [Related]
9. Screening of carbohydrate-specific phage antibodies against recombinant human erythropoietin (rhuEPO) using a phage display antibody library: preliminary study. Mi J; Ding X; Zhao M; Chang W; Guo Z J Immunoassay Immunochem; 2006; 27(2):115-28. PubMed ID: 16711250 [TBL] [Abstract][Full Text] [Related]
10. Immunization of mice with DNA coding for the variable regions of anti-idiotypic antibody generates antigen-specific response. Vani J; Nayak R; Shaila MS Vaccine; 2007 Jun; 25(26):4922-30. PubMed ID: 17531360 [TBL] [Abstract][Full Text] [Related]
11. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies. Barbin K; Stieglmaier J; Saul D; Stieglmaier K; Stockmeyer B; Pfeiffer M; Lang P; Fey GH J Immunother; 2006; 29(2):122-33. PubMed ID: 16531813 [TBL] [Abstract][Full Text] [Related]
12. Janusin: new molecular design for bispecific reagents. Traunecker A; Lanzavecchia A; Karjalainen K Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo modifications of recombinant and human IgG antibodies. Liu H; Ponniah G; Zhang HM; Nowak C; Neill A; Gonzalez-Lopez N; Patel R; Cheng G; Kita AZ; Andrien B MAbs; 2014; 6(5):1145-54. PubMed ID: 25517300 [TBL] [Abstract][Full Text] [Related]
14. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506 [TBL] [Abstract][Full Text] [Related]
15. In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase. Warnock D; Bai X; Autote K; Gonzales J; Kinealy K; Yan B; Qian J; Stevenson T; Zopf D; Bayer RJ Biotechnol Bioeng; 2005 Dec; 92(7):831-42. PubMed ID: 16187338 [TBL] [Abstract][Full Text] [Related]
16. [Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity]. Huang J; Shibaguchi H; Masahide K Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Sep; 22(5):650-3. PubMed ID: 16948917 [TBL] [Abstract][Full Text] [Related]
17. High-level expression of full-length antibodies using trans-complementing expression vectors. Bianchi AA; McGrew JT Biotechnol Bioeng; 2003 Nov; 84(4):439-44. PubMed ID: 14574701 [TBL] [Abstract][Full Text] [Related]
18. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Li H; Sethuraman N; Stadheim TA; Zha D; Prinz B; Ballew N; Bobrowicz P; Choi BK; Cook WJ; Cukan M; Houston-Cummings NR; Davidson R; Gong B; Hamilton SR; Hoopes JP; Jiang Y; Kim N; Mansfield R; Nett JH; Rios S; Strawbridge R; Wildt S; Gerngross TU Nat Biotechnol; 2006 Feb; 24(2):210-5. PubMed ID: 16429149 [TBL] [Abstract][Full Text] [Related]
19. Aglycosylated antibodies and the methods of making and using them: WO2008030564. Jefferis R Expert Opin Ther Pat; 2009 Jan; 19(1):101-5. PubMed ID: 19441902 [TBL] [Abstract][Full Text] [Related]
20. Construction of single-chain Fv with two possible CDR3H conformations but similar inter-molecular forces that neutralize bovine herpesvirus 1. Koti M; Farrugia W; Nagy E; Ramsland PA; Kaushik AK Mol Immunol; 2010 Feb; 47(5):953-60. PubMed ID: 20006385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]